Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting β2m and CIITA
- Development stage
- Preclinical
- Lead developer
- The First Affiliated Hospital of Sun Yat-sen University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intra-arterial
01
Overview
siRNA targeting β2m and CIITA (siβ2m+CIITA) is a preclinical combination of cholesterol-modified small interfering RNAs (siRNAs) designed to downregulate major histocompatibility complex (MHC) class I and class II expression. Developed by researchers at Sun Yat-Sen University, the therapy is delivered ex vivo to donor kidneys during normothermic machine perfusion (NMP) prior to transplantation. By silencing beta-2-microglobulin (β2m), a key component of MHC class I, and the class II transactivator (CIITA), a master regulator of MHC class II, the treatment aims to mitigate acute rejection and improve renal allograft survival and function.
- Other names
- cholesterol-modified siRNA targeting β2m and CIITAsiβ2m + siCIITAsiβ2m+CIITA
02
Targets
CIITA (MHC class II transactivator)
Beyond the preview
Go deeper on siRNA targeting β2m and CIITA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting β2m and CIITA.